Prometheus Biosciences Stock Current Valuation
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Valuation analysis of Prometheus Biosciences helps investors to measure Prometheus Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Prometheus Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Prometheus Biosciences is based on 3 months time horizon. Increasing Prometheus Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Prometheus Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prometheus Stock. However, Prometheus Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 199.92 | Real 150.07 | Hype 199.92 |
The intrinsic value of Prometheus Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Prometheus Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Prometheus Biosciences helps investors to forecast how Prometheus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prometheus Biosciences more accurately as focusing exclusively on Prometheus Biosciences' fundamentals will not take into account other important factors: Prometheus Biosciences Company Current Valuation Analysis
Prometheus Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Prometheus Biosciences Current Valuation | 4.39 B |
Most of Prometheus Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prometheus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Prometheus Biosciences has a Current Valuation of 4.39 B. This is 69.43% lower than that of the Biotechnology sector and 5.48% lower than that of the Health Care industry. The current valuation for all United States stocks is 73.59% higher than that of the company.
Prometheus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prometheus Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prometheus Biosciences could also be used in its relative valuation, which is a method of valuing Prometheus Biosciences by comparing valuation metrics of similar companies.Prometheus Biosciences is currently under evaluation in current valuation category among its peers.
Prometheus Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X | |||
| Price To Sales | 627.82 X | |||
| Revenue | 6.81 M | |||
| Gross Profit | (106.04 M) | |||
| EBITDA | (145.78 M) | |||
| Net Income | (141.75 M) | |||
| Cash And Equivalents | 95.96 M | |||
| Cash Per Share | 2.35 X | |||
| Total Debt | 14.76 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 13.32 X | |||
| Book Value Per Share | 14.62 X | |||
| Cash Flow From Operations | (123.25 M) | |||
| Short Ratio | 3.97 X | |||
| Earnings Per Share | (3.54) X | |||
| Target Price | 190.0 | |||
| Number Of Employees | 97 | |||
| Beta | -0.49 | |||
| Market Capitalization | 9.56 B | |||
| Total Asset | 740.77 M | |||
| Retained Earnings | (331.09 M) | |||
| Working Capital | 685.33 M | |||
| Current Asset | 135.99 M | |||
| Current Liabilities | 24.54 M | |||
| Net Asset | 740.77 M |
About Prometheus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prometheus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prometheus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prometheus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |